Vinflunine-gemcitabine versus vinflunine-carboplatin as first-line chemotherapy in cisplatin-unfit patients with advanced urothelial carcinoma: Results of an international randomized phase II trial (JASINT1)

Annals of Oncology

Volumn 27, Issue 3, 2016, Pages 449-454

  De Santis, Maria ^a,b   Wiechno, P J ^c   Bellmunt, J ^d   Lucas, C ^e   Su, W C ^f   Albiges, L ^g   Lin, C C ^h   Senkus Konefka, E ⁱ   Flechon, A ^j   Mourey, L ^k   Necchi, A ^l   Loidl, W C ^m   Retz, M M ⁿ   Vaissiere N ^e   Culine, S ^o  

^a LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

^b UNIVERSITY OF WARWICK   (United Kingdom)

^c INSTITUTE OF ONCOLOGY   (Poland)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e INSTITUT DE RECHERCHE PIERRE FABRE   (France)

^f NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^g INSTITUT GUSTAVE ROUSSY   (France)

^h NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

ⁱ MEDICAL UNIVERSITY OF GDANSK   (Poland)

^j CENTRE LÉON BÉRARD   (France)

^k INSTITUT CLAUDIUS REGAUD   (France)

^l NATIONAL CANCER INSTITUTE   (Italy)

^m KH Barmherzige Schwestern Linz ^*  (Austria)

ⁿ TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^o SAINT LOUIS HOSPITAL   (France)

more..

Author keywords

Bladder cancer; Cisplatin ineligible; Renal impairment; Urothelial carcinoma; vinflunine

Indexed keywords

CARBOPLATIN; CISPLATIN; CREATININE; GEMCITABINE; VINFLUNINE; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; VINBLASTINE;

ABDOMINAL PAIN; ADVANCED CANCER; ADVANCED UROTHELIAL CARCINOMA; AGED; ALOPECIA; ANEMIA; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; BLADDER TUMOR; BONE MARROW SUPPRESSION; BONE SCINTISCANNING; CANCER MORTALITY; CAUSE OF DEATH; COMPUTER ASSISTED TOMOGRAPHY; CONSTIPATION; CONTROLLED STUDY; CREATININE CLEARANCE; CYSTECTOMY; DECREASED APPETITE; DIARRHEA; DISEASE CONTROL; DISTANT METASTASIS; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; DYSPHAGIA; FATIGUE; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; FEVER; FLATULENCE; FOLLOW UP; HEALTH STATUS; HEMATOLOGIC DISEASE; HISTOPATHOLOGY; HUMAN; ILEUS; INFECTION; LIVER METASTASIS; MAJOR CLINICAL STUDY; METASTASIS; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL PAIN; NAUSEA; NEPHRECTOMY; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OPEN STUDY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PHLEBITIS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; TRANSITIONAL CELL CARCINOMA; TREATMENT DURATION; TREATMENT PLANNING; TREATMENT RESPONSE; UPPER URINARY TRACT TUMOR; URETHRA TUMOR; URINARY TRACT TUMOR; VISCERAL METASTASIS; VOMITING; WEIGHT REDUCTION; X RAY; ADULT; ANALOGS AND DERIVATIVES; CARCINOMA, TRANSITIONAL CELL; CLINICAL TRIAL; DISEASE FREE SURVIVAL; MALE; MIDDLE AGED; MULTICENTER STUDY; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, TRANSITIONAL CELL; CISPLATIN; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS; VINBLASTINE;

EID: 84959923381     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdv609     Document Type: Article

References (24)

1. International Agency for Research on Cancer, World Health Organisation. GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012. http://globocan.iarc.fr (18 August 2014, date last accessed).
2. Bellmunt J, Orsola A, Leow JJ et al. Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014; 25(suppl 3): iii40-iii48.
3. Witjes JA, Compérat E, Cowan NC et al. EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines. Eur Urol 2014; 65 (4): 778-792.
4. Galsky MD, Hahn NM, Rosenberg J et al. A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. Lancet Oncol 2011; 12(3): 211-214.
5. De Santis M, Bellmunt J, Mead G et al. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol 2012; 30: 191-199.
6. Galsky MD, Hahn NM, Rosenberg J et al. Treatment of patients with metastatic urothelial cancer 'unfit' for Cisplatin-based chemotherapy. J Clin Oncol 2011; 29 (17): 2432-2438.
7. Javlor® European Public Assessment Report doc EMEA/CHMP/370293/2009.
8. Bellmunt J, Théodore C, Demkov T et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinumcontaining regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol 2009; 27: 4454-4461.
9. Isambert N, Delord JP, Tourani JM et al. How to manage intravenous vinflunine in cancer patients with renal impairment: results of a pharmacokinetic and tolerability phase I study. Br J Clin Pharmacol 2014; 77(3): 498-508.
10. Tournoux-Facon C, Senellart H, Lemarie E et al. Phase I and pharmacokinetic study of IV vinflunine in combination with gemcitabine for treatment of advanced non-small cell lung cancer in chemonaive patients. J Thorac Oncol 2011; 6(7): 1247-1253.
11. Tournoux-Facon C, Robinet G, Pinel MC et al. Phase I and pharmacokinetic study of IV vinflunine in combination with carboplatin in chemonaive patients with advanced non-small cell lung cancer. Am J Clin Oncol 2012; 35(4): 378-385.
12. Bamias A, Moulopoulos LA, Koutras A et al. The combination of gemcitabine and carboplatin as first-line treatment in patients with advanced urothelial carcinoma. A phase II study of the Hellenic Cooperative Oncology Group. Cancer 2006; 106: 297-303.
13. De Santis M, Bellmunt J, Mead G et al. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer 'unfit' for cisplatin-based chemotherapy: phase II-results of EORTC study 30986. J Clin Oncol 2009; 27(33): 5634-5639.
14. Culine S, Fléchon A, Guillot A et al. Gemcitabine or gemcitabine plus oxaliplatin in the first-line treatment of patients with advanced transitional cell carcinoma of the urothelium unfit for cisplatin-based chemotherapy: a randomized phase 2 study of the French Genitourinary Tumor Group (GETUG V01). Eur Urol 2011; 60(6): 1251-1257.
15. Galsky MD, Iasonos A, Mironov S et al. Phase II trial of dose-dense doxorubicin plus gemcitabine followed by paclitaxel plus carboplatin in patients with advanced urothelial carcinoma and impaired renal function. Cancer 2007; 109(3): 549-555.
16. Bajorin DF, Dodd PM, Mazumdar M et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol 1999; 17: 3173-3181.
17. Balar AV, Apolo AB, Ostrovnaya I et al. Phase II study of gemcitabine, carboplatin, and bevacizumab in patients with advanced unresectable or metastatic urothelial cancer. J Clin Oncol 2013; 31(6): 724-730.
18. Venook A, Egorin M, Rosner G et al. Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer Leukemia Group B 9565. J Clin Oncol 2000; 18(14): 2780-2787.
19. Serrate C, Pouessel D, Gauthier H et al. Vinflunine for the treatment of metastatic transitional cell carcinoma: recent evidence from clinical trials and observational studies. Clin Invest 2014; 4(4): 305-311.
20. Meluch AA, Greco FA, Burris HA, III et al. Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2001; 19 (12): 3018-3024.
21. Albers P, Park SI, Niegisch G et al. Randomized phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment [German Association of Urological Oncology (AUO) trial AB 20/99]. Ann Oncol 2011; 22(2): 288-294.
22. Pond GR, Bellmunt J, Fougeray R et al. Impact of response to prior chemotherapy in patients with advanced urothelial carcinoma receiving second-line therapy: implications for trial design. Clin Genitourin Cancer 2013; 11(4): 495-500.
23. Sonpavde G, Bellmunt J, Rosenberg JE et al. Patient eligibility and trial design for the salvage therapy of advanced urothelial carcinoma. Clin Genitourin Cancer 2014; 12(6): 395-398.
24. Krajewski KM, Fougeray R, Bellmunt J et al. Optimisation of the size variation threshold for imaging evaluation of response in patients with platinum-refractory advanced transitional cell carcinoma of the urothelium treated with vinflunine. Eur J Cancer 2012; 48(10): 1495-1502.